Advertisement

Cancer Immunology, Immunotherapy

, Volume 57, Issue 11, pp 1711–1717 | Cite as

The “A, B and C” of Her-2 DNA vaccine development

  • Wei-Zen WeiEmail author
  • Jennifer Jacob
  • Olga Radkevich-Brown
  • Paula Whittington
  • Yi-chi M. Kong
Symposium Paper

Abstract

Introduction

The development of Her-2 DNA vaccine has progressed through three phases that can be categorized as phase “A”: the pursuit of Her-2 as a tumor-associated “antigen”, phase “B”: tilting the “balance” between tumor immunity and autoimmunity and phase “C”: the on-going “clinical trials”.

Materials and methods

In phase “A”, a panel of human ErbB-2 or Her-2 plasmids were constructed to encode non-transforming Her-2 derivatives. The immunogenicity and anti-tumor activity of Her-2 DNA vaccines were tested in human Her-2 transgenic mice with or without the depletion of regulatory T cells (Tregs). However, Treg depletion or other immune modulating regimens may increase the risk of autoimmunity. In phase “B”, the balance between tumor immunity and autoimmunity was assessed by monitoring the development of experimental autoimmune thyroiditis (EAT). To test the efficacy of Her-2 DNA vaccines in cancer patients, clinical trials have been initiated in phase “C”.

Results and conclusions

Significant anti-Her-2 and anti-tumor activity was observed when Her-2 transgenic mice were electro-vaccinated after Treg depletion. Susceptibility to EAT was also enhanced by Treg depletion and there was mutual amplification between Her-2 immunity and EAT development. Although Tregs regulate both EAT and Her-2 immunity, their effector mechanisms may differ. It may be possible to amplify tumor immunity with improved strategies that can by-pass undue autoimmunity. Critical information will be revealed in the next decade to expedite the development of cancer vaccines.

Keywords

Her-2 ErbB-2 DNA vaccine Cancer vaccine Autoimmunity 

References

  1. 1.
    Hung MC, Lau YK (1999) Basic science of HER-2/neu: a review. Semin Oncol 26(12 Suppl 4):51–59PubMedGoogle Scholar
  2. 2.
    Slamon DJ, Godolphin W, Jones LA et al (1989) Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244:707–712PubMedCrossRefGoogle Scholar
  3. 3.
    Ben-Levy R, Paterson HF, Marshall CJ et al (1994) A single autophosphorylation site confers oncogenicity tothe Neu/ErbB-2 receptor and enables coupling to the MAP kinase pathway. EMBO J 13:3302–3311PubMedGoogle Scholar
  4. 4.
    Wada T, Qian XL, Greene MI (1990) Intermolecular association of the p185neu protein and EGF receptor modulates EGF receptor function. Cell 61:1339–1347PubMedCrossRefGoogle Scholar
  5. 5.
    Wei WZ, Shi WP, Galy A et al (1999) Protection against mammary tumor growth by vaccination with full-length, modified human ErbB-2 DNA. Int J Cancer 81:748–754PubMedCrossRefGoogle Scholar
  6. 6.
    Romond EH, Perez EA, Bryant J et al (2005) Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353:1673–1684PubMedCrossRefGoogle Scholar
  7. 7.
    Pilon SA, Piechocki MP, Wei WZ (2001) Vaccination with cytoplasmic ErbB-2 DNA protects mice from mammary tumor growth without anti-ErbB-2 antibody. J Immunol 167:3201–3206PubMedGoogle Scholar
  8. 8.
    Kiessling R, Wei WZ, Herrmann F et al (2002) Cellular immunity to the Her-2/neu protooncogene. Adv Cancer Res 85:101–144PubMedCrossRefGoogle Scholar
  9. 9.
    Piechocki MP, Pilon SA, Wei WZ (2002) Quantitative measurement of anti-ErbB-2 antibody by flow cytometry and ELISA. J Immunol Methods 259:33–42PubMedCrossRefGoogle Scholar
  10. 10.
    Pilon SA, Kelly C, Wei WZ (2003) Broadening of epitope recognition during immune rejection of ErbB-2-positive tumor prevents growth of ErbB-2-negative tumor. J Immunol 170:1202–1208PubMedGoogle Scholar
  11. 11.
    Piechocki MP, Ho YS, Pilon S et al (2003) Human ErbB-2 (Her-2) transgenic mice: a model system for testing Her-2 based vaccines. J Immunol 171:5787–5794PubMedGoogle Scholar
  12. 12.
    Lindencrona JA, Preiss S, Kammertoens T et al (2004) CD4+ T cell-mediated HER-2/neu-specific tumor rejection in the absence of B cells. Int J Cancer 109:259–264PubMedCrossRefGoogle Scholar
  13. 13.
    Wei WZ, Morris GP, Kong YM (2004) Anti-tumor immunity and autoimmunity: a balancing act of regulatory T cells. Cancer Immunol Immunother 53:73–78PubMedCrossRefGoogle Scholar
  14. 14.
    Miller F, Jones RF, Jacob J et al (2004) From breast cancer immunobiology to her-2 DNA vaccine and autoimmune sequelae. Breast Dis 20:43–51PubMedGoogle Scholar
  15. 15.
    Wei WZ, Jacob JB, Zielinski JF et al (2005) Concurrent induction of antitumor immunity and autoimmune thyroiditis in CD4+ CD25+ regulatory T cell-depleted mice. Cancer Res 65:8471–8478PubMedCrossRefGoogle Scholar
  16. 16.
    Jacob J, Radkevich O, Forni G et al (2006) Activity of DNA vaccines encoding self or heterologous Her-2/neu in Her-2 or neu transgenic mice. Cell Immunol 240:96–106PubMedCrossRefGoogle Scholar
  17. 17.
    Piechocki MP, Pilon SA, Wei WZ (2001) Complementary antitumor immunity induced by plasmid DNA encoding secreted and cytoplasmic human ErbB-2. J Immunol 167:3367–3374PubMedGoogle Scholar
  18. 18.
    Jacob JB, Kong YM, Meroueh C et al (2007) Control of Her-2 tumor immunity and thyroid autoimmunity by MHC and regulatory T cells. Cancer Res 67:7020–7027PubMedCrossRefGoogle Scholar
  19. 19.
    Ursini-Siegel J, Schade B, Cardiff RD et al (2007) Insights from transgenic mouse models of ERBB2-induced breast cancer. Nat Rev Cancer 7:389–397PubMedCrossRefGoogle Scholar
  20. 20.
    Rovero S, Amici A, Carlo ED et al (2000) DNA vaccination against rat her-2/Neu p185 more effectively inhibits carcinogenesis than transplantable carcinomas in transgenic BALB/c mice. J Immunol 165:5133–5142PubMedGoogle Scholar
  21. 21.
    Piechocki MP, Yoo GH, Dibbley SK et al (2007) Breast cancer expressing the activated HER2/neu is sensitive to gefitinib in vitro and in vivo and acquires resistance through a novel point mutation in the HER2/neu. Cancer Res 67:6825–6843PubMedCrossRefGoogle Scholar
  22. 22.
    Shimizu J, Yamazaki S, Sakaguchi S (1999) Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity. J Immunol 163:5211–5218PubMedGoogle Scholar
  23. 23.
    Reilly RT, Gottlieb MB, Ercolini AM et al (2000) HER-2/neu is a tumor rejection target in tolerized HER-2/neu transgenic mice. Cancer Res 60:3569–3576PubMedGoogle Scholar
  24. 24.
    Singh R, Paterson Y (2007) In the FVB/N HER-2/neu transgenic mouse both peripheral and central tolerance limit the immune response targeting HER-2/neu induced by Listeria monocytogenes-based vaccines. Cancer Immunol Immunother 56:927–938PubMedCrossRefGoogle Scholar
  25. 25.
    Bos R, van DS, van HT et al (2005) Expression of a natural tumor antigen by thymic epithelial cells impairs the tumor-protective CD4+ T-cell repertoire. Cancer Res 65:6443–6449PubMedCrossRefGoogle Scholar
  26. 26.
    Gallo P, Dharmapuri S, Nuzzo M et al (2005) Xenogeneic immunization in mice using HER2 DNA delivered by an adenoviral vector. Int J Cancer 113:67–77PubMedCrossRefGoogle Scholar
  27. 27.
    Pupa SM, Iezzi M, Di CE et al (2005) Inhibition of mammary carcinoma development in HER-2/neu transgenic mice through induction of autoimmunity by xenogeneic DNA vaccination. Cancer Res 65:1071–1078PubMedGoogle Scholar
  28. 28.
    Tegerstedt K, Lindencrona JA, Curcio C et al (2005) A single vaccination with polyomavirus VP1/VP2Her2 virus-like particles prevents outgrowth of HER-2/neu-expressing tumors. Cancer Res 65:5953–5957PubMedCrossRefGoogle Scholar
  29. 29.
    Huang W, Kukes GD (1999) Hashimoto’s thyroiditis: an organ-specific autoimmune disease-pathogenesis and recent developments. Lab Invest 79:1175–1180PubMedGoogle Scholar
  30. 30.
    Canonica GW, Cosulich ME, Croci R et al (1984) Thyroglobulin-induced T-cell in vitro proliferation in Hashimoto’s thyroiditis: identification of the responsive subset and effect of monoclonal antibodies directed to Ia antigens. Clin Immunol Immunopathol 32:132–141PubMedCrossRefGoogle Scholar
  31. 31.
    Vaidya B, Kendall-Taylor P, Pearce SHS (2002) Genetics of endocrine disease: the genetics of autoimmune thyroid disease. J Clin Endocrinol Metab 87:5385–5397PubMedCrossRefGoogle Scholar
  32. 32.
    Kong YM, Lomo LC, Motte RW et al (1996) HLA-DRB1 polymorphism determines susceptibility to autoimmune thyroiditis in transgenic mice: definitive association with HLA-DRB1*0301 (DR3) gene. J Exp Med 184:1167–1172PubMedCrossRefGoogle Scholar
  33. 33.
    Kong YM, David CS, Lomo LC et al (1997) Role of mouse and human class II transgenes in susceptibility to and protection against mouse autoimmune thyroiditis. Immunogenetics 46:312–317PubMedCrossRefGoogle Scholar
  34. 34.
    Vladutiu AO, Rose NR (1971) Autoimmune murine thyroiditis: relation to histocompatibility (H-2) type. Science 174:1137–1139PubMedCrossRefGoogle Scholar
  35. 35.
    Larsen CE, Alper CA (2004) The genetics of HLA-associated disease. Curr Opin Immunol 16:660–667PubMedCrossRefGoogle Scholar
  36. 36.
    Levin L, Ban Y, Concepcion E et al (2004) Analysis of HLA genes in families with autoimmune diabetes and thyroiditis. Hum Immunol 65:640–647PubMedCrossRefGoogle Scholar
  37. 37.
    Esquivel PS, Rose NR, Kong YM (1977) Induction of autoimmunity in good and poor responder mice with mouse thyroglobulin and lipopolysaccharide. J Exp Med 145:1250–1263PubMedCrossRefGoogle Scholar
  38. 38.
    Elrehewy M, Kong YM, Giraldo AA et al (1981) Syngeneic thyroglobulin is immunogenic in good responder mice. Eur J Immunol 11:146–151PubMedCrossRefGoogle Scholar
  39. 39.
    McNeel DG, Knutson KL, Schiffman K et al (2003) Pilot study of an HLA-A2 peptide vaccine using flt3 ligand as a systemic vaccine adjuvant. J Clin Immunol 23:62–72PubMedCrossRefGoogle Scholar
  40. 40.
    Disis ML, Rinn K, Knutson KL et al (2002) Flt3 ligand as a vaccine adjuvant in association with HER-2/neu peptide-based vaccines in patients with HER-2/neu-overexpressing cancers. Blood 99:2845–2850PubMedCrossRefGoogle Scholar
  41. 41.
    Shevach EM (2000) Regulatory T cells in autoimmmunity. Annu Rev Immunol 18:423–449PubMedCrossRefGoogle Scholar
  42. 42.
    Kong YM, Giraldo AA, Waldmann H et al (1989) Resistance to experimental autoimmune thyroiditis: L3T4+ cells as mediators of boththyroglobulin-activated and TSH-induced suppression. Clin Immunol Immunopathol 51:38–54PubMedCrossRefGoogle Scholar
  43. 43.
    Sakaguchi S, Sakaguchi N, Asano M et al (1995) Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 155:1151–1164PubMedGoogle Scholar
  44. 44.
    Morris GP, Chen L, Kong YM (2003) CD137 signaling interferes with activation and function of CD4+CD25+ regulatory T cells in induced tolerance to experimental autoimmune thyroiditis. Cell Immunol 226:20–29PubMedCrossRefGoogle Scholar
  45. 45.
    Morris GP, Yan Y, David CS et al (2005) H2A- and H2E-derived CD4+CD25+ regulatory T cells: a potential role in reciprocal inhibition by class II genes in autoimmune thyroiditis. J Immunol 174:3111–3116PubMedGoogle Scholar
  46. 46.
    Morris GP, Kong YM (2006) Interference with CD4(+)CD25(+) T-cell-mediated tolerance to experimental autoimmune thyroiditis by glucocorticoid-induced tumor necrosis factor receptor monoclonal antibody. J Autoimmun 26:24–31PubMedCrossRefGoogle Scholar
  47. 47.
    Maker AV, Attia P, Rosenberg SA (2005) Analysis of the cellular mechanism of antitumor responses and autoimmunity in patients treated with CTLA-4 blockade. J Immunol 175:7746–7754PubMedGoogle Scholar
  48. 48.
    Blansfield JA, Beck KE, Tran K et al (2005) Cytotoxic T-lymphocyte-associated antigen-4 blockage can induce autoimmune hypophysitis in patients with metastatic melanoma and renal cancer. J Immunother 28:593–598PubMedCrossRefGoogle Scholar
  49. 49.
    Attia P, Phan GQ, Maker AV et al (2005) Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J Clin Oncol 23:6043–6053PubMedCrossRefGoogle Scholar
  50. 50.
    Maker AV, Phan GQ, Attia P et al (2005) Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a phase I/II study. Ann Surg Oncol 12:1005–1016PubMedCrossRefGoogle Scholar
  51. 51.
    Robinson MR, Chan CC, Yang JC et al (2004) Cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma: a new cause of uveitis. J Immunother 27:478–789PubMedCrossRefGoogle Scholar
  52. 52.
    Phan GQ, Yang JC, Sherry RM et al (2003) Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci USA 100:8372–8377PubMedCrossRefGoogle Scholar
  53. 53.
    Rose NR, Bacon LD, Sundick RS et al (1977) Genetic regulation in autoimmune thyroiditis. In: Talal N (ed) Autoimmunity: genetics, immunologic, virologic, and clinical aspects. Academic Press, New York, pp 63–87Google Scholar

Copyright information

© Springer-Verlag 2008

Authors and Affiliations

  • Wei-Zen Wei
    • 1
    Email author
  • Jennifer Jacob
    • 1
  • Olga Radkevich-Brown
    • 1
  • Paula Whittington
    • 1
  • Yi-chi M. Kong
    • 1
  1. 1.Karmanos Cancer Institute and Department of Immunology and MicrobiologyWayne State UniversityDetroitUSA

Personalised recommendations